Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – FDA authorises Qorvo Biotechnologies’ rapid Covid-19 antigen test – JOYSBIO Covid-19 neutralising antibody rapid test 98% accurate

16 Apr 2021 (Last Updated April 16th, 2021 09:47)

Qorvo Biotechnologies has announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to its Qorvo Omnia SARS-CoV-2 antigen test. The test is now approved to detect viral antigens from SARS-CoV-2 in nasal swabs of suspected individuals.

A clinical study carried out in Italy has found the JOYSBIO Covid-19 neutralising antibody rapid test kit to be 98.05% effective in verifying neutralising antibodies after subjects got vaccinated with the Pfizer-BioNTech vaccine. The inexpensive kit delivers results in 25 to 30 minutes, and could be used to analyse people’s immunity status.

Seegene has announced that its Italian subsidiary, Arrow Diagnostics, has secured the public procurement worth over $99.04m, the largest volume of tender for its Italian branch. As per the agreement, Arrow Diagnostics is expected to supply about 7.15 million Covid-19 diagnostic tests along with extraction reagents to the Italian Ministry of Defence. The Covid-19 diagnostic tests will be distributed across 17 regions including Liguria, Lombardy, Tuscany, and Veneto.